A large claims-based study found no increased risk for most outcomes with first-trimester stimulant exposure during pregnancy, but higher risks when use continued later in pregnancy.
A new cohort study from Australia found that lithium use during pregnancy was linked to a two-fold increased risk of spontaneous preterm birth, along with higher risks of a large for gestational age infant and congenital cardiac malformations. We review how these findings compare with prior research and what they mean for women with bipolar disorder who are using — or considering — lithium during pregnancy.
New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information.
Dr. Marlene Freeman warns that valproic acid poses severe, well-established reproductive risks and should not be used by anyone who could become pregnant.
Topiramate exposure in early pregnancy is linked to higher rates of major malformations and more specifically to increased risk of oral clefts, with risk rising at higher doses.
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
Using valproic acid (Depakote) during pregnancy raises important safety concerns, including increased risks of congenital malformations and neurodevelopmental disorders.
Despite FDA warnings, valproate is still prescribed to women of reproductive age, placing children at risk for birth defects and neurodevelopmental disorders.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; however, medical organizations and experts support the important role of SSRIs and other medications in supporting maternal mental health.
Prenatal exposure to valproate is linked to increased risk of autism spectrum disorder, ADHD, lower IQ, and intellectual disability, especially at higher doses.
